Appeal for Increasing the Impact of Pharmacovigilance

Overview

Journal Drug Saf

Specialties Pharmacology
Toxicology

Date 2023 Dec 19

PMID 38114758

Authors

Agnes C Kant

Affiliations

Soon will be listed here.

Citing Articles

Might We Come Together on a Paradigm Shift to Manage ICSRs with a Decentralized Data Model?.

Smith L, Glaser M, Kempf D, Roman X, Artlich C, Patel M Drug Saf. 2025; .

PMID: 40056291 DOI: 10.1007/s40264-025-01539-4.

Pharmacovigilance in the Community: A Special-Interest Group of the International Society of Pharmacovigilance.

Elhawary M, Noss R, Alj L, Younus M, Alkhakany M, Rostom H Drug Saf. 2025; 48(3):203-207.

PMID: 39779631 DOI: 10.1007/s40264-024-01513-6.

Views on the Development and Use of a New Digital Adverse Drug Event Reporting Platform in Australia: A Qualitative Study.

Gebreyohannes E, Thornton C, Thiessen M, de Vries S, Coombs G, Hwang I Drug Saf. 2024; 48(2):179-190.

PMID: 39487335 PMC: 11785647. DOI: 10.1007/s40264-024-01489-3.

References

Patel T, Patel P, Bhalla H, Dwivedi P, Bajpai V, Kishore S . Impact of suspected adverse drug reactions on mortality and length of hospital stay in the hospitalised patients: a meta-analysis. Eur J Clin Pharmacol. 2022; 79(1):99-116. DOI: 10.1007/s00228-022-03419-7. View

Pirmohamed M, James S, Meakin S, Green C, Scott A, Walley T . Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004; 329(7456):15-9. PMC: 443443. DOI: 10.1136/bmj.329.7456.15. View

Lazarou J, Pomeranz B, Corey P . Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279(15):1200-5. DOI: 10.1001/jama.279.15.1200. View

van Hunsel F, Gardarsdottir H, de Boer A, Kant A . Measuring the impact of pharmacovigilance activities, challenging but important. Br J Clin Pharmacol. 2019; 85(10):2235-2237. PMC: 6783581. DOI: 10.1111/bcp.14042. View

Pacurariu A, Coloma P, van Haren A, Genov G, Sturkenboom M, Straus S . A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee. Drug Saf. 2014; 37(12):1059-66. DOI: 10.1007/s40264-014-0240-1. View

Lester J, Neyarapally G, Lipowski E, Graham C, Hall M, Dal Pan G . Evaluation of FDA safety-related drug label changes in 2010. Pharmacoepidemiol Drug Saf. 2013; 22(3):302-5. DOI: 10.1002/pds.3395. View

Bate A, Stegmann J . Safety of medicines and vaccines - building next generation capability. Trends Pharmacol Sci. 2021; 42(12):1051-1063. DOI: 10.1016/j.tips.2021.09.007. View

van Hunsel F, de Jong E, Gross-Martirosyan L, Hoekman J . Signals from the Dutch national spontaneous reporting system: Characteristics and regulatory actions. Pharmacoepidemiol Drug Saf. 2021; 30(8):1115-1122. DOI: 10.1002/pds.5246. View

Swen J, van der Wouden C, Manson L, Abdullah-Koolmees H, Blagec K, Blagus T . A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023; 401(10374):347-356. DOI: 10.1016/S0140-6736(22)01841-4. View

10.

Harmark L, Raine J, Leufkens H, Ralph Edwards I, Moretti U, Sarinic V . Patient-Reported Safety Information: A Renaissance of Pharmacovigilance?. Drug Saf. 2016; 39(10):883-90. DOI: 10.1007/s40264-016-0441-x. View

11.

Kosse L, Weits G, Vonkeman H, Spuls P, van den Bemt B, Tas S . Immune-mediated inflammatory disease patients' preferences in adverse drug reaction information regarding biologics. Expert Opin Drug Saf. 2020; 19(8):1049-1054. DOI: 10.1080/14740338.2020.1781090. View

12.

Davis S, Zabotka L, Desai R, Wang S, Maro J, Coughlin K . Use of Electronic Health Record Data for Drug Safety Signal Identification: A Scoping Review. Drug Saf. 2023; 46(8):725-742. PMC: 11635839. DOI: 10.1007/s40264-023-01325-0. View

13.

Bate A, Hobbiger S . Artificial Intelligence, Real-World Automation and the Safety of Medicines. Drug Saf. 2020; 44(2):125-132. DOI: 10.1007/s40264-020-01001-7. View

14.

Bate A, Luo Y . Artificial Intelligence and Machine Learning for Safe Medicines. Drug Saf. 2022; 45(5):403-405. PMC: 9112276. DOI: 10.1007/s40264-022-01177-0. View

15.

Ball R, Dal Pan G . "Artificial Intelligence" for Pharmacovigilance: Ready for Prime Time?. Drug Saf. 2022; 45(5):429-438. PMC: 9112277. DOI: 10.1007/s40264-022-01157-4. View

16.

Aronson J . Artificial Intelligence in Pharmacovigilance: An Introduction to Terms, Concepts, Applications, and Limitations. Drug Saf. 2022; 45(5):407-418. DOI: 10.1007/s40264-022-01156-5. View

17.

Noguchi Y, Tachi T, Teramachi H . Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform. 2021; 22(6). DOI: 10.1093/bib/bbab347. View

18.

Drelich E, Religioni U, Chung K, Kazmierczak J, Blicharska E, Neumann-Podczaska A . The Quality and Reliability of Information in the Summaries of Product Characteristics. Int J Environ Res Public Health. 2022; 19(4). PMC: 8872284. DOI: 10.3390/ijerph19042185. View

19.

Way D, Blazsin H, Lofstedt R, Bouder F . Pharmaceutical Benefit-Risk Communication Tools: A Review of the Literature. Drug Saf. 2016; 40(1):15-36. DOI: 10.1007/s40264-016-0466-1. View

20.

Furedi A . The public health implications of the 1995 'pill scare'. Hum Reprod Update. 2000; 5(6):621-6. DOI: 10.1093/humupd/5.6.621. View